 |
|
|
| |
LONG-ACTING CABOTEGRAVIR + RILPIVIRINE
FOR HIV MAINTENANCE:
FLAIR WEEK 48 RESULTS
|
| |
| |
Reported by Jules Levin
CROI 2019 March 4-7 Seattle
WEBCAST: http://www.croiwebcasts.org/console/player/41309?mediaType=slideVideo&&crd_fl=0&ssmsrq=1554571747827&ctms=5000&csmsrq=5139
Chloe Orkin,1 Keikawus Arasteh,2 Miguel Gorgolas Hernandez-Mora,3 Vadim Pokrovsky,4 Edgar T. Overton,5 Pierre-Marie Girard,6 Shinichi Oka,7 Ronald D'Amico,8 David Dorey,9
Sandy Griffith,8 David A Margolis,8 Peter Williams,10 Wim Parys,10 William R Spreen8
1Queen Mary University, London, United Kingdom; 2EPIMED GmbH, Berlin, Germany; 3 Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain;
4Central Institute of Epidemiology, Moscow, Russian Federation; 5University of Alabama at Birmingham, Birmingham, AL, United States;
6Hopital Saint Antoine, Paris, France; 7National Center for Global Health and Medicine, Tokyo, Japan; 8ViiV Healthcare, Research Triangle Park, NC, United States;
9GlaxoSmithKline, Mississauga, Ontario, Canada; 10Janssen Research and Development, Beerse, Belgium
|
| |
|
|
|
|
|
